201 related articles for article (PubMed ID: 38781610)
1. Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis.
Tiwari P; Verma S; Washimkar KR; Nilakanth Mugale M
Int Immunopharmacol; 2024 Jun; 135():112269. PubMed ID: 38781610
[TBL] [Abstract][Full Text] [Related]
2. Glycolysis Reprogramming in Idiopathic Pulmonary Fibrosis: Unveiling the Mystery of Lactate in the Lung.
Yan P; Liu J; Li Z; Wang J; Zhu Z; Wang L; Yu G
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203486
[TBL] [Abstract][Full Text] [Related]
3. In vitro co-culture studies and the crucial role of fibroblast-immune cell crosstalk in IPF pathogenesis.
Thiam F; Phogat S; Abokor FA; Osei ET
Respir Res; 2023 Nov; 24(1):298. PubMed ID: 38012580
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and immunity in IPF pathogenesis and treatment.
Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
[TBL] [Abstract][Full Text] [Related]
5. Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.
Suryadevara V; Ramchandran R; Kamp DW; Natarajan V
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549377
[TBL] [Abstract][Full Text] [Related]
6. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the interplay between vital organelle stress and oxidative stress in idiopathic pulmonary fibrosis.
Mohanan A; Washimkar KR; Mugale MN
Biochim Biophys Acta Mol Cell Res; 2024 Mar; 1871(3):119676. PubMed ID: 38242330
[TBL] [Abstract][Full Text] [Related]
8. Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis.
O'Dwyer DN; Ashley SL; Moore BB
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L590-601. PubMed ID: 27474089
[TBL] [Abstract][Full Text] [Related]
9. The potential role of interleukin (IL)-25/IL-33/thymic stromal lymphopoietin (TSLP) on the pathogenesis of idiopathic pulmonary fibrosis.
Xu X; Dai H; Zhang J
Clin Respir J; 2022 Nov; 16(11):696-707. PubMed ID: 36082495
[TBL] [Abstract][Full Text] [Related]
10. The Epithelial-Immune Crosstalk in Pulmonary Fibrosis.
Planté-Bordeneuve T; Pilette C; Froidure A
Front Immunol; 2021; 12():631235. PubMed ID: 34093523
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?
Thatcher TH; Freeberg MAT; Myo YPA; Sime PJ
Pharmacol Ther; 2023 Jul; 247():108460. PubMed ID: 37244406
[TBL] [Abstract][Full Text] [Related]
12. Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy.
Chen R; Dai J
J Mol Med (Berl); 2023 Aug; 101(8):905-915. PubMed ID: 37289208
[TBL] [Abstract][Full Text] [Related]
13. Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis.
Andersson CK; Andersson-Sjöland A; Mori M; Hallgren O; Pardo A; Eriksson L; Bjermer L; Löfdahl CG; Selman M; Westergren-Thorsson G; Erjefält JS
Respir Res; 2011 Oct; 12(1):139. PubMed ID: 22014187
[TBL] [Abstract][Full Text] [Related]
14. Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis.
Renaud L; da Silveira WA; Takamura N; Hardiman G; Feghali-Bostwick C
Front Immunol; 2020; 11():383. PubMed ID: 32210969
[TBL] [Abstract][Full Text] [Related]
15. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.
Hewlett JC; Kropski JA; Blackwell TS
Matrix Biol; 2018 Oct; 71-72():112-127. PubMed ID: 29625182
[TBL] [Abstract][Full Text] [Related]
17. Glycolysis and beyond in glucose metabolism: exploring pulmonary fibrosis at the metabolic crossroads.
Wang Y; Wang X; Du C; Wang Z; Wang J; Zhou N; Wang B; Tan K; Fan Y; Cao P
Front Endocrinol (Lausanne); 2024; 15():1379521. PubMed ID: 38854692
[TBL] [Abstract][Full Text] [Related]
18. Anti-fibrotic strategies and pulmonary fibrosis.
Gunatilaka A; Zhang S; Tan WSD; G Stewart A
Adv Pharmacol; 2023; 98():179-224. PubMed ID: 37524487
[TBL] [Abstract][Full Text] [Related]
19. Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis.
Vittal R; Mickler EA; Fisher AJ; Zhang C; Rothhaar K; Gu H; Brown KM; Emtiazjoo A; Lott JM; Frye SB; Smith GN; Sandusky GE; Cummings OW; Wilkes DS
PLoS One; 2013; 8(10):e76451. PubMed ID: 24204629
[TBL] [Abstract][Full Text] [Related]
20. PTX3 Regulation of Inflammation, Hemostatic Response, Tissue Repair, and Resolution of Fibrosis Favors a Role in Limiting Idiopathic Pulmonary Fibrosis.
Doni A; Mantovani A; Bottazzi B; Russo RC
Front Immunol; 2021; 12():676702. PubMed ID: 34276664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
